Provided is a quinoline derivative for treating extranodal NK/T cell lymphoma. The provided compound I or a pharmaceutically acceptable salt thereof can be used for treating extranodal NK/T cell lymphoma patients resistant to asparagine, especially recurrent or refractory extranodal NK/T cell lymphoma patients resistant to asparagine, with results of efficacy evaluation showing relieved symptoms and prolonged survival in the patients.